New treatment for severe lung complications from sepsis
Official title: Aerosolized Chemically Modified Tetracycline Nanoformulation for the Treatment of Acute Respiratory Distress Syndrome
Funded at Cmtx Biotech, INC. · NIH-10950503 · Data updated 2026-11-12
This study is testing a new inhaled medication to help people with acute respiratory distress syndrome (ARDS) caused by sepsis, aiming to reduce lung inflammation and improve breathing for those at risk.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Cmtx Biotech, INC. NIH-funded |
| Lab location | 1 site (Kings Park, United States) |
| Project start | March 1, 2025 |
| Project end | February 28, 2027 |
| Funding year | 2025 |
| Award (this year) | $887,354 |
| NIH project number | 4R42HL166050-02 |
| Project ID | NIH-10950503 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are adults over 21 years old who are experiencing sepsis and are at risk of developing acute respiratory distress syndrome.
✕Less likely to help
Patients who do not have sepsis or are not at risk for ARDS may not benefit from this research.
What this research studies
This research focuses on developing a new aerosolized drug formulation aimed at treating acute respiratory distress syndrome (ARDS) that can occur in patients suffering from sepsis. The approach involves using a modified form of tetracycline, which is delivered directly to the lungs to target inflammation and improve respiratory function. By investigating the mechanisms of how sepsis leads to ARDS, the research aims to provide a specific treatment option for this serious condition. Patients who are at risk of developing ARDS due to sepsis may be eligible for this innovative treatment.
Why it matters
Potential benefit: If successful, this research could provide a targeted therapy for patients suffering from ARDS caused by sepsis, potentially reducing mortality rates and improving recovery outcomes.
How similar studies have gone: While there have been advancements in treating ARDS, this specific approach using aerosolized chemically modified tetracycline is novel and has not been extensively tested in clinical settings.
Where this research is happening
-
Cmtx Biotech, INC.
Kings Park, United States Active
Researchers
- Principal investigator: Kollisch-Singule, Michaela Christina — Cmtx Biotech, INC.
- Study coordinator: Kollisch-Singule, Michaela Christina
Related research
Other NIH-funded projects on the same topics.
-
Identifying ARDS patients who may benefit from paralytics guided by high-frequency clinical data
This grant aims to help doctors figure out which adults with ARDS are most likely to benefit from paralytic medications using detailed bedside data and electronic health records.
-
Resilience endotypes and early ARDS detection using biomarkers and AI
A Duke University team is using biomarkers and smart data analysis to detect ARDS early and uncover patterns that predict how patients recover.
-
PAR1’s role in lung lymphatics and a new therapy approach for ARDS
This grant explores how the thrombin receptor PAR1 affects lung lymphatics to understand and ultimately reduce lung injury in ARDS patients.
-
Dead space and inhaled nitric oxide in pediatric ARDS
This project looks at whether measuring dead space and using inhaled nitric oxide can help improve outcomes for children with acute respiratory distress syndrome.
-
Immune, hormone, and muscle energy links to recovery after ARDS
This project looks at why some ARDS survivors have ongoing weakness and how immune, hormone, and muscle energy factors might influence recovery.</n>
-
Understanding why some people with severe lung injury get worse and how to tailor therapy
A patient-focused program that looks at why people develop sepsis-associated ARDS and how their bodies respond, with the goal of guiding better, personalized treatments.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.